Acadia Pharmaceuticals (ACAD) Bullish Stance Reiterated at Cowen; All Eyes on PDP PDUFA, ADP Enrollment
Cowen analyst Ritu Baral reiterated an Outperform rating and $50 price target on Acadia Pharmaceuticals (NASDAQ: ACAD) following Q3 results ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)